RP5063: Phase II started

Reviva began the double-blind, placebo-controlled, international Phase II REFRESH trial to compare 15, 30 or 50 mg daily RP5063 vs. 15 mg daily aripiprazole in 228 patients. Bristol-Myers Squibb Co. ...